CareDx, Inc 8-K
PositiveEarnings
Higher transplant testing volume and patient & digital solutions growth drove record preliminary Q4 revenue of ≈$108M, +25% Y/Y.
Filed 2026-01-12 07:08 ET
- 2.02 Results of Operations
- 9.01 Financial Statements and Exhibits
Summary
Preliminary Q4 and FY2025 results. CareDx reported record revenue across all segments; Q4 testing-services volume rose 17% Y/Y and patient & digital solutions revenue rose 47% Y/Y, driving growth across its transplant-focused business.
Key Figures
| Metric | Q4 2025 | FY2025 |
|---|---|---|
| Revenue | ≈$108M, +25% Y/Y | ≈$380M, +14% Y/Y |
| Testing services revenue | ≈$78M, +23% Y/Y | ≈$274M, +10% Y/Y |
| Testing services volume | ≈53,000, +17% Y/Y | ≈200,000, +14% Y/Y |
| Patient & digital solutions revenue | ≈$17M, +47% Y/Y | ≈$57M, +31% Y/Y |
| Product revenue | ≈$13M, +17% Y/Y | ≈$48M, +19% Y/Y |
- Average revenue per test was ≈$1,470 in Q4, including ≈$5M of prior-period revenue.
- CareDx repurchased $12M of shares in Q4, or 773,000 shares at an average $15.79 per share; FY2025 repurchases were $88M, or 5.8 million shares at an average $15.16 per share.
- Cash, cash equivalents and marketable securities were ≈$200M at 12/31/2025.
Guidance
No guidance in this filing.
Investor Takeaways
- Watch whether testing-services volume and patient & digital solutions revenue continue growing in 2026 as CareDx builds commercial momentum and advances its Transplant+ innovation pipeline; continued growth would support the strategy, while deceleration would challenge it.
The summary is written by an AI model reading the filing.
Model 005 · prompt v173 · 2026-11-02 11:14:52Z